This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.
Cutaneous melanoma is an aggressive skin cancer which, in the metastatic setting, has a historic 5-year survival rate of \<30%. In 2023, about 97,610 new cases of melanoma were estimated to occur in the US, with about 7,990 deaths. GLOBACON reported 324,635 cases of melanoma globally in 2020, which constituted about 1.7% of all cancers and 57,043 melanoma-associated deaths. The parent trial of this corollary study is a randomized, open-label, multicenter phase 3 study comparing the anti-tumor activity of fixed-dose combination (FDC) of fianlimab + cemiplimab versus the FDC of relatlimab + nivolumab (referred to as Opdualag™) in participants with unresectable or metastatic melanoma (stage III-IV). This corollary study will explore the immunological response of CD8, CD4, and other immune cells in the blood and tumor microenvironment of patients in response to the provided treatments.
Study Type
OBSERVATIONAL
Enrollment
20
Patients treated with Fianlimab 1600 mg + Cemiplimab 350 mg under protocol NCT06246916
Patients treated with Relatlimab 160 mg + Nivolumab 480 mg under protocol NCT06246916
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
RECRUITINGSingle-cell analysis of CD4+ T cells
Single-cell RNAseq analysis of CD8+ T cells and other immune cells in blood and tumor biopsies.
Time frame: Up to 39 months
Immunological response of CD4+ T cells
Single-cell analysis of CD4+ T cell (frequency) and other immune cells in blood and tumor biopsies. Analysis of single-cell RNA-seq data to obtain gene module scores for each CD4+ T cell or myeloid cell in whole blood and tumor biopsies will be classified as binary: 1 (co-expressing cytotoxic and exhaustion gene modules) or 0 (no co-expression).
Time frame: Up to 39 months
Multiplexed immunofluorescence
Degree of immune infiltration major immune subsets in the tumor microenvironment. The density of immune cells relative to the total number of cells in the tumor tissue will be calculated for each patient.
Time frame: Up to 39 months
Multiplexed immunofluorescence
Frequencies of major immune subsets in the tumor microenvironment. The density of immune cells relative to the total number of cells in the tumor tissue will be calculated for each patient.
Time frame: Up to 39 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.